Search for: "Sanofi"
Results 161 - 180
of 1,195
Sort by Relevance
|
Sort by Date
5 Feb 2023, 9:37 pm
Noonan -- Facing what is likely to be something of an uphill battle in seeking to have the Federal Circuit's decision against it in Amgen v Sanofi overturned before a not always patent-friendly Supreme Court, Amgen in late December filed its opening brief addressing the Question Presented in the granted certiorari petition: Whether enablement is governed by the statutory requirement that the specification teach those skilled in the art to "make and use" the invention, 35… [read post]
5 Feb 2023, 3:51 pm
AstraZeneca won in the District of Delaware, while Sanofi Aventis and Novo Nordisk lost at the District of New Jersey. [read post]
4 Feb 2023, 5:28 pm
Per the EFF, Sanofi-Aventis backed down: “Under terms of Tuesday’s settlement, AcompliaReport.com keeps its domain name, as long as there is a disclaimer stating... [read post]
3 Feb 2023, 6:50 am
Sanofi (Full Scope Enablement: How much description is enough to satisfy the written description requirement). [read post]
31 Jan 2023, 2:59 pm
Sanofi (March 27): When a patent applicant must provide a description of its invention that would enable a “skilled artisan” to make and use the invention, what must the applicant show to meet that requirement? [read post]
19 Jan 2023, 10:19 am
U.S. court denies Sandoz challenge to Sanofi MS drug exclusivity. [read post]
12 Jan 2023, 10:46 am
The post Sanofi CEO: We Don’t Have A Leaky Bathtub appeared first on Above the Law. [read post]
7 Jan 2023, 7:48 am
Sanofi and Juno v. [read post]
5 Jan 2023, 10:43 am
Sanofi, on which the Supreme Court granted certiorari this past November. [read post]
5 Jan 2023, 10:43 am
Sanofi, on which the Supreme Court granted certiorari this past November. [read post]
4 Jan 2023, 1:15 pm
Sanofi case. [read post]
4 Jan 2023, 1:15 pm
Sanofi case. [read post]
27 Dec 2022, 4:33 pm
Sanofi (C-443/12), Georgetown University v. [read post]
22 Dec 2022, 7:59 am
Sanofi, No. 21-757, with merits briefs due beginning December 27, 2022. [read post]
13 Dec 2022, 4:49 am
Sanofi (enablement). [read post]
5 Dec 2022, 1:03 pm
Sanofi U.S. [read post]
5 Dec 2022, 2:37 am
We asked Sanofi, the maker of Act, to explain these changes, as well as calling their consumer line. [read post]
29 Nov 2022, 9:18 am
Sanofi warrants reconsideration. [read post]
29 Nov 2022, 9:18 am
Sanofi warrants reconsideration. [read post]
28 Nov 2022, 9:07 pm
Food and Drug Administration (FDA) announced its approval of Eli Lilly's Rezvoglar (insulin glargine-aglr) product as an interchangeable biosimilar to Sanofi's Lantus (insulin glargine). [read post]
